RE:RE:RE:RE:CG OncologyDe_man, you again have missed my point that while it took ONCY $450 million to develop an intravenously delivered OV, CG Oncology has yet to come to the point of having an IV product. Delivering a product intravessically (intratumorally) like CG Oncology is doing to treat superficial bladder cancer, is a completley different story than treating metastatic cancer which has become widespread and beyond the muscle wall. Furthermore, your caustic posts both here and on Stocktwits either suggests that your agenda is completely different than you are trying to say or you don't know the essence of the subject matter.